{"id":61857,"date":"2026-03-30T18:08:31","date_gmt":"2026-03-30T10:08:31","guid":{"rendered":"https:\/\/flcube.com\/?p=61857"},"modified":"2026-03-30T18:08:32","modified_gmt":"2026-03-30T10:08:32","slug":"gsks-bepirovirsen-receives-ema-review-acceptance-for-chronic-hepatitis-b-pioneering-triple-mechanism-aso-therapy","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=61857","title":{"rendered":"GSK\u2019s Bepirovirsen Receives EMA Review Acceptance for Chronic Hepatitis B, Pioneering Triple-Mechanism ASO Therapy"},"content":{"rendered":"\n

GlaxoSmithKline plc<\/strong> (GSK, NYSE: GSK<\/a>) announced that the European Medicines Agency (EMA)<\/strong> has accepted for review its Marketing Authorization Application (MAA)<\/strong> for bepirovirsen<\/strong>, an investigational antisense oligonucleotide (ASO)<\/strong> for the treatment of chronic hepatitis B (CHB)<\/strong> in adults. If approved, bepirovirsen would become the first therapy to combine three distinct mechanisms<\/strong>\u2014viral replication inhibition, HBsAg reduction, and immune reactivation<\/strong>\u2014in a single agent, potentially enabling a functional cure<\/strong> for a disease affecting over 250 million people globally<\/strong>.<\/p>\n\n\n\n

Regulatory Milestone<\/h2>\n\n\n\n
Event<\/th>Status<\/th><\/tr><\/thead>
MAA Submission<\/strong><\/td>Accepted by EMA (validated for review)<\/td><\/tr>
Indication<\/strong><\/td>Chronic hepatitis B in adults<\/td><\/tr>
Therapeutic Class<\/strong><\/td>Antisense oligonucleotide (ASO)<\/td><\/tr>
Next Steps<\/strong><\/td>Standard EMA review timeline (~12\u201318 months); potential approval in 2027<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

This marks a critical step toward making bepirovirsen the first disease-modifying therapy<\/strong> for CHB beyond lifelong nucleos(t)ide analogs.<\/p>\n\n\n\n

Triple Mechanism of Action<\/h2>\n\n\n\n

Bepirovirsen is designed to bind hepatitis B virus (HBV) mRNA and pregenomic RNA<\/strong>, triggering their degradation via RNase H1. This leads to:<\/p>\n\n\n\n

    \n
  1. Inhibition of viral genome replication<\/strong> \u2013 Reduces production of new virions<\/li>\n\n\n\n
  2. Reduction of hepatitis B surface antigen (HBsAg)<\/strong> \u2013 Lowers levels of this key immune-tolerance driver<\/li>\n\n\n\n
  3. Immune system reactivation<\/strong> \u2013 Restores T-cell and B-cell responses, increasing chances of durable functional cure<\/strong> (defined as sustained HBsAg loss with or without anti-HBs seroconversion)<\/li>\n<\/ol>\n\n\n\n

    Unlike current therapies that suppress replication but rarely achieve HBsAg loss (<1\u20133% annually), bepirovirsen targets the root cause of viral persistence<\/strong>.<\/p>\n\n\n\n

    Clinical Context & Unmet Need<\/h2>\n\n\n\n